News Contact Us

Ofatumumab shows better efficacy versus Teriflunomide in RMS studies

Author : Paroma Bhattacharya | Published Date : 2019-08-31 
  • Head to head Phase III ASCLEPIOS studies I & II of OMB157 (ofatumumab) have revealed considerable superiority in reducing the ARR (annualized relapsed rate) in patients suffering from RMS (relapsing forms of multiple sclerosis) in comparison with terinuflomide.
  • OMB157 also met the secondary key endpoints of delaying time to confirmed progression of disability.
  • Ofatumumab safety profile was in keeping with the Phase II results, delivering sustained effectiveness.

Danish biotechnology expert Genmab A/S has reportedly announced Novartis’ positive results for OMB157 (ofatumumab) observed from the ASCLEPIOS I & II studies in Phase III. The studies, conducted to test the effectiveness and safety of monthly ofatumumab 20g (administered subcutaneously) vs once-daily teriflunomide 14g (administered orally) in adult patients with relapsing multiple sclerosis forms (RMS), showed that both treatments met primary endpoints, with ofatumumab showing profound and clinically significant reduction in confirmed relapse numbers, assessed as the ARR.

Key secondary endpoints for delay in time to confirm disability progression were met as well.

According to Genmab CEO, Jan van de Winkel, PhD, the information gathered through these studies indicates a potential turning point for ofatumumab and reinforces the belief that, if approved, it could become the 1st subcutaneously administered B-cell therapy for RMS, which patients can self-administer. He further expressed Genmab’s anticipation for the authorities’ feedback and delight for this new stage in the development of ofatumumab.

Novartis, that carries the right to develop and market of atumumab licensed by Genmab, has started plans to begin submissions to health authorities by the end of the year, on the basis of data collected during the ASCLEPIOS studies.

Phase III ASCLEPIOS I & II study results will be presented on the 13th of September in a late-breaker presentation format, at the esteemed 35th Congress of the ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis). The event is expected to take place from 11th to 13th September 2019, in Stockholm.

Source Credit: https://www.globenewswire.com/news-release/2019/08/30/1908824/0/en/Ofatumumab-Demonstrates-Superiority-Versus-Teriflunomide-in-Two-Head-to-Head-Phase-III-Multiple-Sclerosis-Studies.html


About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma Bhattacharya, having completed her post-graduation in Journalism and Mass Communication, started her career in writing with resourceful and informative content development across diverse fields. Having dealt in myriad topics ranging from business to real estate, she now pens down articles for fractovia.org and other portals. She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

Impossible Burgers to soon hit shelves in grocery stores in California

Published Date: 2019-09-21         Author: Paroma Bhattacharya

While the American market is dominated by meat-eating consumers, it is evolving its diet preferences by accepting plant-based food in its meal. Additionally, young people are also expanding their food horizons, in search of new protein alternatives. This has fueled a growth in sales of plant-based b... Read More

Plex partners with Lionsgate for a new ad-supported streaming service

Published Date: 2019-09-20         Author: Paroma Bhattacharya

Online movies and video streaming are gaining popularity recently. Various media streaming firms are collaborating with a number of entertainment companies in order to set themselves apart from the growing competition in the online video streaming field as well as to offer better video streaming exp... Read More

Flipkart partners with Japanese firm MINISO ahead of festive season

Published Date: 2019-09-17         Author: Paroma Bhattacharya

Festivals in India are a key point of market growth for companies. The festive season attracts a lot of companies to invest in various market landscapes of the country, particularly multinational and foreign companies. This further leads to various collaborations between foreign companies and Indian... Read More

© 2019 Fractovia. All Rights Reserved